What's next after metformin? focus on sulphonylurea: add-on or combination therapy

Item

http://www.wikidata.org/entity/Q26786524

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

What's next after metformin? focus on sulphonylurea: add-on or combination therapy

@ast

What's next after metformin? focus on sulphonylurea: add-on or combination therapy

@en

What's next after metformin? focus on sulphonylurea: add-on or combination therapy

@nl

type

Item

label

What's next after metformin? focus on sulphonylurea: add-on or combination therapy

@ast

What's next after metformin? focus on sulphonylurea: add-on or combination therapy

@en

What's next after metformin? focus on sulphonylurea: add-on or combination therapy

@nl

prefLabel

What's next after metformin? focus on sulphonylurea: add-on or combination therapy

@ast

What's next after metformin? focus on sulphonylurea: add-on or combination therapy

@en

What's next after metformin? focus on sulphonylurea: add-on or combination therapy

@nl

P1476

What's next after metformin? focus on sulphonylurea: add-on or combination therapy

@en

P2093

Chee P Chong

http://www.w3.org/2001/XMLSchema#string

Phei C Lim

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Cardiovascular outcomes in trials of oral diabetes medications: a systematic review

Alpha-glucosidase inhibitors for type 2 diabetes mellitus

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events: A comparison of glyburide with other secretagogues and with insulin

P304

606

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18549/PHARMPRACT.2015.03.606

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26445623

http://www.w3.org/2001/XMLSchema#string

P921

metformin

P932

4582747

http://www.w3.org/2001/XMLSchema#string